DE2059937A1 - Verfahren zur Herstellung von Polynucleotiden - Google Patents
Verfahren zur Herstellung von PolynucleotidenInfo
- Publication number
- DE2059937A1 DE2059937A1 DE19702059937 DE2059937A DE2059937A1 DE 2059937 A1 DE2059937 A1 DE 2059937A1 DE 19702059937 DE19702059937 DE 19702059937 DE 2059937 A DE2059937 A DE 2059937A DE 2059937 A1 DE2059937 A1 DE 2059937A1
- Authority
- DE
- Germany
- Prior art keywords
- poly
- enzyme
- mice
- animals
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 17
- 108091033319 polynucleotide Proteins 0.000 title claims description 6
- 239000002157 polynucleotide Substances 0.000 title claims description 6
- 102000040430 polynucleotide Human genes 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 3
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 8
- JPXZQMKKFWMMGK-KQYNXXCUSA-N IDP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 JPXZQMKKFWMMGK-KQYNXXCUSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 6
- ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 claims description 5
- 241000589149 Azotobacter vinelandii Species 0.000 claims description 4
- 159000000003 magnesium salts Chemical class 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 23
- 229920000642 polymer Polymers 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 101001066878 Homo sapiens Polyribonucleotide nucleotidyltransferase 1, mitochondrial Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 102000002681 Polyribonucleotide nucleotidyltransferase Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000000910 agglutinin Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000006872 enzymatic polymerization reaction Methods 0.000 description 3
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 101710186708 Agglutinin Proteins 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 150000004712 monophosphates Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
- 101710161876 ATP-dependent zinc metalloprotease YME1L1 Proteins 0.000 description 1
- 241001167556 Catena Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US00197118A US3796631A (en) | 1970-11-09 | 1971-11-09 | Processes for preparing polynucleotides |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7040268A FR2112784A5 (enExample) | 1970-11-09 | 1970-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2059937A1 true DE2059937A1 (de) | 1972-05-18 |
Family
ID=9063972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19702059937 Pending DE2059937A1 (de) | 1970-11-09 | 1970-12-05 | Verfahren zur Herstellung von Polynucleotiden |
Country Status (6)
| Country | Link |
|---|---|
| BE (1) | BE775021A (enExample) |
| CA (1) | CA979831A (enExample) |
| DE (1) | DE2059937A1 (enExample) |
| FR (1) | FR2112784A5 (enExample) |
| GB (1) | GB1375001A (enExample) |
| NL (1) | NL7115407A (enExample) |
-
1970
- 1970-11-09 FR FR7040268A patent/FR2112784A5/fr not_active Expired
- 1970-12-05 DE DE19702059937 patent/DE2059937A1/de active Pending
-
1971
- 1971-11-05 BE BE775021A patent/BE775021A/xx unknown
- 1971-11-08 CA CA127,088A patent/CA979831A/en not_active Expired
- 1971-11-08 GB GB5177571A patent/GB1375001A/en not_active Expired
- 1971-11-09 NL NL7115407A patent/NL7115407A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2112784A5 (enExample) | 1972-06-23 |
| BE775021A (fr) | 1972-05-05 |
| CA979831A (en) | 1975-12-16 |
| GB1375001A (enExample) | 1974-11-27 |
| NL7115407A (enExample) | 1972-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69419244T2 (de) | Zusammensetzungen und methoden zur anwendung von reaktiven antiviralen polymeren | |
| DE60006810T2 (de) | Dicarboxylato-diamin-platin-derivate und zusammensetzungen die diese als antitumormittel enthalten | |
| DE3045078A1 (de) | Nucleasebestaendiger hydrophiler komplex aus polyriboinosinsaeure, verfahren zu seiner herstellung und verwendung desselben | |
| DE2655844C3 (de) | Verfahren zur Herstellung antitumorwirksamer Substanzen | |
| DE1668033A1 (de) | Neue Ferrihydroxyd-carbohydrat-Koplexe und Verfahren zu deren Herstellung | |
| DE69018132T2 (de) | Verfahren zur Herstellung einer das Wachstum von Bifidobakterien fördernden Substanz. | |
| DE69023708T2 (de) | Anti-hiv-heilmittel. | |
| DE69307895T2 (de) | Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin | |
| DE2059937A1 (de) | Verfahren zur Herstellung von Polynucleotiden | |
| DE2723451C2 (enExample) | ||
| DE2451360C2 (de) | 9-Hydroxyellipticin, Verfahren zu dessen Herstellung und seine Verwendung als Arzneimittel | |
| AT396251B (de) | Verfahren zur herstellung von polynucleotiden, so erhaltene produkte und diese enthaltende pharmazeutische zusammensetzungen | |
| Chirigos et al. | Effectiveness of Cytoxan against intracerebrally and subcutaneously inoculated mouse lymphoid leukemia L1210 | |
| DE2528460A1 (de) | Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans | |
| US3796631A (en) | Processes for preparing polynucleotides | |
| DE2064296C2 (de) | Verfahren zur Herstellung eines injizierbaren Mittels gegen Viren der Mäuseleukämien | |
| DE1809119C3 (de) | Infarktprophylaktikum | |
| DE2036935A1 (de) | Verfahren zur Herstellung von Isoniazid derivaten | |
| DE1717100A1 (de) | Verfahren zur Herstellung von anticarcinomatoesen Praeparaten haemolytischer Streptococcen | |
| CH660125A5 (de) | Gereinigtes, entgiftetes endotoxin enthaltende zusammensetzung. | |
| DE2221281C3 (de) | Pharmazeutische Zubereitungen mit entzündungshemmender und analgetischer Wirkung | |
| DE2415812A1 (de) | Poly(5-hydroxycytidylsaeuren) | |
| DE69019148T2 (de) | D-asparaginsäure-beta-hydroxamat zur behandlung viraler infektionen und tumoren. | |
| DE966040C (de) | Haarpflegemittel | |
| DE68917752T2 (de) | Verfahren zur Produktion von kristallinen Formen von Lithium-, Potassium- und Magnesiumsalzen von Cytidindiphosphocholin, die so erhaltenen kristallinen Formen und ihre pharmazeutische Verwendung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |